Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Frontiers in immunology·2026
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

Should natalizumab be used despite JC virus positivity? No.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine.

Neurology and therapy·2025
Same author

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.

Journal of neurology, neurosurgery, and psychiatry·2024
Same author

Assessing disease progression and treatment response in progressive multiple sclerosis.

Nature reviews. Neurology·2024
Same journal

New frontiers in acute reperfusion therapy for ischaemic stroke: from recanalisation to selection, delivery and safety.

Therapeutic advances in neurological disorders·2026
Same journal

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same journal

Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.

Therapeutic advances in neurological disorders·2026
Same journal

Narcolepsy with co-occurring epilepsy: diagnostic pitfalls and management strategy.

Therapeutic advances in neurological disorders·2026
Same journal

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model.

Therapeutic advances in neurological disorders·2026
Same journal

Residual early neurological deterioration following dual antiplatelet in stroke: post hoc analysis of the ATAMIS trial.

Therapeutic advances in neurological disorders·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Neutralizing antibodies against interferon-Beta.

Per Soelberg Sorensen1

  • 1Danish Multiple Sclerosis Research Center Department of Neurology 2082, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark. pss@rh.dk

Therapeutic Advances in Neurological Disorders
|December 25, 2010
PubMed
Summary
This summary is machine-generated.

Neutralizing antibodies (NAbs) can reduce interferon-beta (IFN-ß) effectiveness in multiple sclerosis patients. Long-term studies show high NAb titers negatively impact disease activity, necessitating therapy changes.

Keywords:
antiinterferon antibodiesbinding antibodiesbioactivityinterferon-betamultiple sclerosisneutralizing antibodies

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

Related Experiment Videos

Last Updated: Jun 5, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Neutralizing antibodies (NAbs) pose a challenge for multiple sclerosis (MS) patients undergoing interferon-beta (IFN-ß) therapy.
  • While binding antibodies (BAbs) are common, only a subset of patients develop NAbs, which can impede treatment efficacy.

Purpose of the Study:

  • To evaluate the impact of neutralizing antibodies (NAbs) on the efficacy of interferon-beta (IFN-ß) treatment in multiple sclerosis (MS).
  • To define criteria for assessing NAb positivity and guide therapeutic decisions based on NAb titers.

Main Methods:

  • Utilized in vitro assays, including cytopathic effect (CPE) and MxA induction assays, to detect and quantify NAbs against IFN-ß.
  • Analyzed data from long-term clinical trials (≥3 years) to correlate NAb titers with disease activity and progression.

Main Results:

  • High titers of NAbs (>20 neutralizing units/ml) significantly reduce or abolish the in vivo response to IFN-ß.
  • Long-term studies demonstrate a detrimental effect of NAbs on relapses, MRI disease activity, and disease progression in MS patients.
  • Low and intermediate NAb titers present ambiguous clinical implications, requiring further assessment.

Conclusions:

  • Persistent high NAb titers indicate a lack of therapeutic efficacy, warranting a change in treatment strategy.
  • For patients with low to intermediate NAb titers, treatment decisions should incorporate in vivo mRNA MxA induction and clinical disease activity assessments.